Analytical Data
-
基因名
BCL6
-
简介
BCL6 is a key transcriptional repressor of germinal centers and regulates multiple biological functions and lineages. It forms a complex with corepressors and histone deacetylase, directly binds to 5'-TTCCTAGAA-3', and inhibits genes involved in differentiation, inflammation, apoptosis and cell cycle control in GC B cells. BCL6 Protein, Human is the recombinant human-derived BCL6 protein, expressed by E. coli , with tag free.
- Application
-
种属
Human
-
表达系统
E. coli
-
标签
Tag Free
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P41182
-
表达区间
M1-C706
-
蛋白长度
Full Length
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The BCL6 protein, a transcriptional repressor, plays a critical role in regulating immune responses and maintaining the balance between cell proliferation and apoptosis. It is predominantly expressed in germinal center B cells and has been implicated in various forms of lymphoma, particularly diffuse large B-cell lymphoma (DLBCL). The dysregulation of BCL6 due to chromosomal translocations and mutations underlines its significance as an oncogenic driver. Research into BCL6 and its functions has highlighted its multifaceted roles in gene expression, cell signaling, and the immune system, making it a promising target for therapeutic interventions. Recent studies have focused on understanding the molecular mechanisms by which BCL6 influences tumorigenesis, including its interactions with other transcription factors, co-repressors, and the epigenetic landscape of target genes. By elucidating these pathways, researchers aim to develop innovative approaches for treating BCL6-driven malignancies, which may include the design of small-molecule inhibitors or monoclonal antibodies that disrupt BCL6 function. Furthermore, BCL6’s involvement in other non-hematological tumors has expanded the scope of its research, suggesting it could also serve as a biomarker for cancer prognosis and therapeutic responses. Thus, the study of BCL6 not only provides insights into lymphoid malignancies but also offers potential avenues for broader cancer therapies.
